Inhibikase Therapeutics (IKT) Retained Earnings (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Retained Earnings for 6 consecutive years, with -$129.9 million as the latest value for Q3 2025.
- On a quarterly basis, Retained Earnings fell 57.86% to -$129.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$129.9 million, a 57.86% decrease, with the full-year FY2024 number at -$37248.0, up 99.94% from a year prior.
- Retained Earnings was -$129.9 million for Q3 2025 at Inhibikase Therapeutics, down from -$118.0 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $165822.0 in Q1 2023 to a low of -$129.9 million in Q3 2025.
- A 5-year average of -$36.3 million and a median of -$22.5 million in 2021 define the central range for Retained Earnings.
- Peak YoY movement for Retained Earnings: soared 100.48% in 2023, then plummeted 11524789.55% in 2025.
- Inhibikase Therapeutics' Retained Earnings stood at -$24.8 million in 2021, then soared by 100.42% to $104718.0 in 2022, then plummeted by 63986.56% to -$66.9 million in 2023, then skyrocketed by 99.94% to -$37248.0 in 2024, then plummeted by 348643.56% to -$129.9 million in 2025.
- Per Business Quant, the three most recent readings for IKT's Retained Earnings are -$129.9 million (Q3 2025), -$118.0 million (Q2 2025), and -$967.0 (Q1 2025).